International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update

Objective: To update the 2016 formal consensus-based guidance for the management of myasthenia gravis (MG) based on the latest evidence in the literature.

Methods: In October 2013, the Myasthenia Gravis Foundation of America appointed a Task Force to develop treatment guidance for MG, and a panel of 15 international experts was convened. The RAND/UCLA appropriateness method was used to develop consensus recommendations pertaining to 7 treatment topics. In February 2019, the international panel was reconvened with the addition of one member to represent South America. All previous recommendations were reviewed for currency, and new consensus recommendations were developed on topics that required inclusion or updates based on the recent literature. Up to 3 rounds of anonymous e-mail votes were used to reach consensus, with modifications to recommendations between rounds based on the panel input. A simple majority vote (80% of panel members voting "yes") was used to approve minor changes in grammar and syntax to improve clarity.

Results: The previous recommendations for thymectomy were updated. New recommendations were developed for the use of rituximab, eculizumab, and methotrexate as well as for the following topics: early immunosuppression in ocular MG and MG associated with immune checkpoint inhibitor treatment.

Conclusion: This updated formal consensus guidance of international MG experts, based on new evidence, provides recommendations to clinicians caring for patients with MG worldwide.

Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

Comment in

[No authors listed] [No authors listed] J Neuroophthalmol. 2021 Jun 1;41(2):272-277. doi: 10.1097/WNO.0000000000001267. J Neuroophthalmol. 2021. PMID: 33999891

Similar articles

Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, Kuntz N, Massey JM, Melms A, Murai H, Nicolle M, Palace J, Richman DP, Verschuuren J, Narayanaswami P. Sanders DB, et al. Neurology. 2016 Jul 26;87(4):419-25. doi: 10.1212/WNL.0000000000002790. Epub 2016 Jun 29. Neurology. 2016. PMID: 27358333 Free PMC article. Review.

Sanders DB, Wolfe GI, Narayanaswami P; MGFA Task Force on MG Treatment Guidance. Sanders DB, et al. Ann N Y Acad Sci. 2018 Jan;1412(1):95-101. doi: 10.1111/nyas.13537. Ann N Y Acad Sci. 2018. PMID: 29381223 Review.

Morren J, Li Y. Morren J, et al. J Neurol Sci. 2020 Mar 15;410:116648. doi: 10.1016/j.jns.2019.116648. Epub 2019 Dec 26. J Neurol Sci. 2020. PMID: 31901719 Review.

Gotterer L, Li Y. Gotterer L, et al. J Neurol Sci. 2016 Oct 15;369:294-302. doi: 10.1016/j.jns.2016.08.057. Epub 2016 Aug 28. J Neurol Sci. 2016. PMID: 27653912 Review.

Silvestri NJ, Wolfe GI. Silvestri NJ, et al. J Clin Neuromuscul Dis. 2014 Jun;15(4):167-78. doi: 10.1097/CND.0000000000000034. J Clin Neuromuscul Dis. 2014. PMID: 24872217 Review.

Cited by

Ohara H, Kikutsuji N, Iguchi N, Kinoshita M. Ohara H, et al. BMC Neurol. 2024 Aug 22;24(1):292. doi: 10.1186/s12883-024-03804-y. BMC Neurol. 2024. PMID: 39174898 Free PMC article.

O'Hare M, Guidon AC. O'Hare M, et al. Nat Rev Neurol. 2024 Sep;20(9):509-525. doi: 10.1038/s41582-024-01001-6. Epub 2024 Aug 9. Nat Rev Neurol. 2024. PMID: 39122934 Review.

Kaminski HJ, Sikorski P, Coronel SI, Kusner LL. Kaminski HJ, et al. J Clin Invest. 2024 Jun 17;134(12):e179742. doi: 10.1172/JCI179742. J Clin Invest. 2024. PMID: 39105625 Free PMC article. Review.

Inan B, Orhan IG, Bekircan-Kurt CE, Erdem-Ozdamar S, Tan E. Inan B, et al. Ir J Med Sci. 2024 Aug 1. doi: 10.1007/s11845-024-03763-w. Online ahead of print. Ir J Med Sci. 2024. PMID: 39088160

Song J, Huan X, Chen Y, Luo Y, Zhong H, Wang Y, Yang L, Xi C, Yang Y, Xi J, Zheng J, Wu Z, Zhao C, Luo S. Song J, et al. Ther Adv Neurol Disord. 2024 Jul 26;17:17562864241261602. doi: 10.1177/17562864241261602. eCollection 2024. Ther Adv Neurol Disord. 2024. PMID: 39072008 Free PMC article.

References

    1. Sanders DB, Wolfe GI, Benatar M, et al. . International consensus guidance for management of myasthenia gravis: executive summary. Neurology 2016;87:419–425. - PMC - PubMed
    1. Fitch K, Bernstein SJ, Aguilar MD, et al. . The RAND/UCLA Appropriateness Method User's Manual. [online]. Available at: rand.org/pubs/monograph_reports/MR1269.html. Accessed July 10, 2020.
    1. Wolfe GI, Kaminski HJ, Aban IB, et al. . Randomized trial of thymectomy in myasthenia gravis. N Engl J Med 2016;375:511–522. - PMC - PubMed
    1. Wolfe GI, Kaminski HJ, Aban IB, et al. . Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial. Lancet Neurol 2019;18:259–268. - PMC - PubMed
    1. Gronseth GS, Barohn R, Narayanaswami P. Practice advisory: thymectomy for myasthenia gravis (practice parameter update): report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology 2020;94:705–709. - PubMed